Overview

The Efficacy and Safety of Utidelone Plus Tirelizumab and Bevacizumab for Advanced or Metastatic Triple-negative Breast Cancer (UTILIZABLE) ：Single-arm, Prospective, Open Clinical Study

Status:
Recruiting

Trial end date:
2026-10-30

Target enrollment:

Participant gender:

Summary

This is a multicenter, open-label, single-arm clinical study designed to evaluate the safety and efficacy of Utidelone plus Tirelizumab and Bevacizumab for advanced or metastatic triple-negative breast cancer (TNBC).

Phase:

Phase 2

Details

Lead Sponsor:

Huihua Xiong

Treatments:

Bevacizumab